HF
TTNP

HRT Financial’s Titan Pharmaceuticals TTNP Stock Holding History

HRT Financial’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,605
Closed -$29K – 3519
2022
Q2 		$29K Buy
+2,605
New +$32.5K ﹤0.01% 2567
2019
Q4 		– Sell
-33
Closed -$5K – 1652
2019
Q3 		$5K Buy
+33
New +$14.9K ﹤0.01% 1361

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's TTNP Position: Q3 2022 in Review

HRT Financial sold out of Titan Pharmaceuticals (TTNP) in Q3 2022, closing a stake of 2,605 shares — an estimated $29K sold.

HRT Financial first reported a position in TTNP in Q3 2019 and held it in 2 quarters. The position peaked at $29K in Q2 2022. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2022.

  • HRT Financial reported no remaining Titan Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • HRT Financial sold 2,605 Titan Pharmaceuticals shares in Q3 2022, an estimated $29K.
  • HRT Financial first reported a position in Titan Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • HRT Financial's Titan Pharmaceuticals position peaked at $29K in Q2 2022.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.